Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients
SC Cheatham, MR Fleming, DP Healy… - International journal of …, 2013 - Elsevier
The study objective was to evaluate steady-state pharmacokinetics and pharmacodynamics
of piperacillin and tazobactam administered by prolonged infusion in obese patients …
of piperacillin and tazobactam administered by prolonged infusion in obese patients …
Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients
EK Chung, SC Cheatham, MR Fleming… - The Journal of …, 2015 - Wiley Online Library
The study objective was to evaluate the population pharmacokinetics and
pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in …
pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in …
Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual
D Newman, MH Scheetz, OA Adeyemi… - Annals of …, 2007 - journals.sagepub.com
Objective: To report pharmacokinetic alterations and optimal dosing of piperacillin/
tazobactam in an obese patient. Case Summary: A 39-year-old morbidly obese (weight 167 …
tazobactam in an obese patient. Case Summary: A 39-year-old morbidly obese (weight 167 …
Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients
AW Sturm, N Allen, KD Rafferty, DN Fish… - … : The Journal of …, 2014 - Wiley Online Library
Study Objective To evaluate the steady‐state pharmacokinetic and pharmacodynamic
parameters of piperacillin in morbidly obese, surgical intensive care patients. Design Open …
parameters of piperacillin in morbidly obese, surgical intensive care patients. Design Open …
Population pharmacokinetics of piperacillin in nonobese, obese, and morbidly obese critically ill patients
The treatment of infections in critically ill obese and morbidly obese patients is challenging
because of the combined physiological changes that result from obesity and critical illness …
because of the combined physiological changes that result from obesity and critical illness …
Repeated Piperacillin-Tazobactam Plasma Concentration Measurements in Severely Obese Versus Nonobese Critically Ill Septic Patients and the Risk of Under–and …
Objective: Obesity and critical illness modify pharmacokinetics of antibiotics, but piperacillin-
tazobactam continuous IV infusion pharmacokinetics has been poorly studied in obese …
tazobactam continuous IV infusion pharmacokinetics has been poorly studied in obese …
Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients
KM Shea, SC Cheatham, MF Wack, DW Smith… - International journal of …, 2009 - Elsevier
The objective of this study was to evaluate the steady-state pharmacokinetics and
pharmacodynamics of piperacillin/tazobactam, administered by prolonged infusion, in …
pharmacodynamics of piperacillin/tazobactam, administered by prolonged infusion, in …
Evaluation of an alternative extended-infusion piperacillin–tazobactam dosing strategy for the treatment of gram-negative infections
EM Winstead, PD Ratliff, RP Hickson… - International journal of …, 2016 - Springer
Introduction To enhance the probability of pharmacodynamic target attainment, piperacillin–
tazobactam can be administered as either a continuous or extended-infusion dosage …
tazobactam can be administered as either a continuous or extended-infusion dosage …
Dosing of piperacillin/tazobactam in a morbidly obese patient
H Deman, J Verhaegen, L Willems… - Journal of antimicrobial …, 2012 - academic.oup.com
Sir, The combination of piperacillin and tazobactam has been shown to be efficacious for the
treatment of intra-abdominal infections, skin and soft tissue infections, bacteraemia and …
treatment of intra-abdominal infections, skin and soft tissue infections, bacteraemia and …
Piperacillin-tazobactam in intensive care units: a review of population pharmacokinetic analyses
I El-Haffaf, JA Caissy, A Marsot - Clinical pharmacokinetics, 2021 - Springer
Piperacillin-tazobactam is a potent β-lactam/β-lactamase inhibitor antibiotic commonly
prescribed in the intensive care unit setting. Admitted patients often show large variability in …
prescribed in the intensive care unit setting. Admitted patients often show large variability in …